Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (7845)	2/7/2003 2:21:19 PM
From: Icebrg	Respond to of 52153

Wilder >>You got me on a couple of those, especially the first one, about infarct size.>> I knew that. It was almost below the belt. And good results from properly done and sized trials should anyhow have a precedence over mere science. But a lack of understanding of the underlying processes will not only increase the risk of late-stage failure, but also increase the hostility factor at FDA (who doesn't like to approve something that not even the sponsor understands). I am not so concerned about the IP matters. In the end most of them will cross-license, it seems. But I agree with you that these things have to be considered. Maybe it is possible to "add" them all together and call it the MPI-factor (for Market Perception Index). Erik